LPA RECEPTOR ANTAGONISTS AND USES THEREOF
The application relates to pyrazole derivatives of the general Formula (I) that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The compounds are useful for the treatment of diseases and conditions including fibrosis and liver diseases such as non-alcohol steatohepa...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
17.11.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The application relates to pyrazole derivatives of the general Formula (I) that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The compounds are useful for the treatment of diseases and conditions including fibrosis and liver diseases such as non-alcohol steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
L'invention concerne des dérivés de pyrazole de formule générale (I) qui se lient au récepteur 1 de l'acide lysophosphatidique (LPAR1) et agissent en tant qu'antagonistes de LPAR1. Les composés sont utiles pour le traitement de maladies et d'états notamment la fibrose et des maladies hépatiques telles que la stéatohépatite non alcoolique (NASH), la maladie pulmonaire interstitielle (ILD), ou la maladie rénale chronique (CKD). |
---|---|
Bibliography: | Application Number: WO2022US28597 |